ADHD
From the Journals
Amphetamine tied to higher risk of new-onset psychosis than methylphenidate
“Psychiatrists may prescribe amphetamine more cautiously than other providers and may screen for risk factors for psychosis.”
Conference Coverage
Eczema increases the risk of impaired mental health among children
WASHINGTON – Many children with eczema and impaired mental health may not be receiving appropriate psychological...
Conference Coverage
Accurately predicting ADHD’s trajectory deemed almost impossible
Dr. Anthony L. Rostain says medication plans should be embedded in a comprehensive treatment approach that starts with psychoeducation.
Conference Coverage
Mood and behavior are different targets for irritability in children
Internalizing and externalizing irritability require distinct therapeutic approaches, said Dr. Gabrielle A. Carlson.
From the Journals
Early lead exposure tied to greater psychopathology in adulthood
Patients who were exposed to high lead levels as children might benefit from increased screening, access to mental health services.
Hard Talk
A prescription for ‘deprescribing’: A case report
Deprescibing can be performed safely and effectively, according to Dr. Nicolas Badre.
From the Journals
Prenatal valproate exposure raises ADHD risk
Children whose mothers took valproate during pregnancy were significantly more likely to have ADHD diagnoses.
From the Journals
ADHD more likely, causes worse outcomes in patients with BD
The lifetime ADHD prevalence rate of 24.6% in patients with bipolar disorder is significantly higher than the incidence in the general population...
MDedge Psychcast
Best of Psychopharmacology: Stimulants, ketamine, benzodiazapines
Latest News
Overshadowed by opioids, meth is back and hospitalizations surge
Amphetamine-related hospitalizations jumped by about 245% during 2008-2015, dwarfing the rise in hospitalizations from other drugs, such as...
Conference Coverage
Jornay PM improves classroom functioning in ADHD
A phase 3 laboratory classroom study confirms the functional benefits of Jornay PM, a novel formulation of methylphenidate.